AXSM AXSOME THERAPEUTICS

Axsome Therapeutics to Participate in Investor Conferences in September

Axsome Therapeutics to Participate in Investor Conferences in September

Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York

Wells Fargo Healthcare Conference on September 5 in Boston

Baird 2024 Global Healthcare Conference on September 11 in New York

Cantor Global Healthcare Conference on September 18 in New York

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will participate in four investor conferences in September:

  • Morgan Stanley 22nd Annual Global Healthcare Conference

    The Company will present on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY
  • 2024 Wells Fargo Healthcare Conference

    The Company will participate in investor meetings on Thursday, September 5, 2024 in Boston, MA
  • Baird 2024 Global Healthcare Conference

    The Company will present on Wednesday, September 11, 2024 at 8:30 a.m. ET in New York, NY
  • 2024 Cantor Global Healthcare Conference

    The Company will present on Wednesday, September 18, 2024 at 9:45 a.m. ET in New York, NY

Live webcasts of the presentations at the Morgan Stanley and Cantor conferences can be accessed on the Investors page of the Company’s website at Replays of the webcasts will be available for approximately 30 days following each event.

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at

Investors:

Mark Jacobson

Chief Operating Officer

(212) 332-3243

Media:

Darren Opland

Director, Corporate Communications

(929) 837-1065



EN
27/08/2024

Underlying

AXSMAXSOME THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AXSOME THERAPEUTICS

 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care ConferenceFireside Chat: Monday, March 2, 2026, at 3:10 p.m. ET in Boston, MA Leerink Partners Global Healthcare ConferenceFireside Chat: Monday, March 9, 2026, at 4:20 p.m. ET in Miami Beach, FL The C...

February 25, 2026 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in...

Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the CLARITY Phase 3 trial of solriamfetol in the treatment of major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms. CLARITY (Clinical Assessment of Response in the T...

February 24, 2026 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financia...

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sal...

February 23, 2026 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthca...

Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 2:00 p.m. ET. A live webcast of the presentation can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsom...

February 18, 2026 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation w...

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch